Digital Pathology-Enabled Artificial Intelligence for Fibrosis Assessment in Metabolic Dysfunction-Associated Steatohepatitis: Needs, Current Progress, and Barriers
{{output}}
Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as the most common chronic liver disorder worldwide. However, most of the candidate drugs, except resmetirom, have failed in the metabolic dysfunction-associated steatohepatitis (MASH... ...
